Who are TransCode Therapeutics, Inc.'s main suppliers?

TransCode Therapeutics, Inc. (RNAZ) key suppliers include: THE-GENERAL-HOSPITAL-CORPORATION, DEFJ, YA-II-PN-LTD. View the full supplier network at chainsifter.com/chain/RNAZ.

Who are TransCode Therapeutics, Inc.'s major customers?

TransCode Therapeutics, Inc. (RNAZ) key customers include: YA-II-PN-LTD, DEFJ-LLC. View the full customer network at chainsifter.com/chain/RNAZ.

What sector is TransCode Therapeutics, Inc. in?

TransCode Therapeutics, Inc. (RNAZ) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

RNAZ Supply Chain: TransCode Therapeutics, Inc. Supplier List & 7 Relationships

3Suppliers

2Customers

2Debt Items

4Related Chains

TransCode Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
THE-GENERAL-HOSPITAL-CORPORATION	THE-GENERAL-HOSPITAL-CORPORATION	90%	Exclusive Patent License Agreement by and between TransCode Therapeutics, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital
DEFJ	DEFJ	80%	On October 8, 2025, under the Purchase Agreement, DEFJ agreed to reimburse the C
YA-II-PN-LTD	YA-II-PN-LTD	80%	the potential issuance of shares of common stock pursuant to a Standby Equity Purchase Agreement (the “SEPA”) by and between us and YA II PN, LTD

TransCode Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
YA-II-PN-LTD	YA-II-PN-LTD	85%	YA II entered into a Standby Equity Purchase Agreement ("SEPA") with the Company dated as of April 6, 2026
DEFJ-LLC	DEFJ-LLC	80%	In connection with our October 2025 acquisition of ABCJ, LLC ("ABCJ") from DEFJ, LLC, ("DEFJ"), DEFJ agreed to reimburse us for up to $3 million of certain expenses

TransCode Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
RNAZ-DEBT-12244	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.
RNAZ-DEBT-12243	Warrants outstanding: 20	90%	xbrl warrant detail from xbrl 2025-12-31.

TransCode Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for TransCode Therapeutics, Inc..

TransCode Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
RNAZ-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 8 tracked holders.

TransCode Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BPTH	Bio-Path Holdings, Inc.	100.00	2
SNYNF	Sanofi	100.00	2
JNJ	Johnson & Johnson	100.00	2
CYTOF	Altamira Therapeutics Ltd.	36.29	1	['spend']

TransCode Therapeutics, Inc. Supply Chain